TSVT (2seventy bio) Insider Ownership : 6.38 % (As of Dec. 15, 2024)

View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 2seventy bio's insider ownership is 6.38%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 2seventy bio's Institutional Ownership is 94.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 2seventy bio's Float Percentage Of Total Shares Outstanding is 82.64%.

2seventy bio Insider Ownership Historical Data

The historical data trend for 2seventy bio's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Insider Ownership Chart

2seventy bio Historical Data

The historical data trend for 2seventy bio can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Insider Ownership	4.12	4.10	4.50	4.50	4.60	6.43	6.40	6.40	6.40	6.38

2seventy bio Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

2seventy bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.2seventybio.com

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Executives

Marcela V. Maus	director	16 RICHMOND CIRCLE, LEXINGTON MA 02421
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Baird William D Iii	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Philip D Gregory	officer: Chief Scientific Officer	POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Kynam Capital Management, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Yue Tang	10 percent owner	221 ELM ROAD, PRINCETON NJ 08540
Nicola Heffron	officer: Chief Operating Officer	2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Daniel Lynch	director
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Ramy Ibrahim	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
William R. Sellers	director	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142